JCCC and UCLA IIIT Seminar Featuring Dr. James Kochenderfer
Treatment of Hematologic Malignancies with Chimeric Antigen Receptor T Cells
12:00 PM - 1:00 PM
Los Angeles, California 90095
James Kochenderfer, M.D.
Investigator, Experimental Transplantation and Immunology Branch
Center for Cancer Research
National Cancer Institute
Dr. Kochenderfer's research is aimed at developing T-cell therapies for hematogic malignancies and genetic engineering of T cells with genes encoding chimeric antigen receptors that target malignancy-associated antigens. This work has led to two clinical trials in which patients receive infusions of T cells that are genetically engineered to specifically recognize and eliminate cells expressing the CD19 antigen, which is expressed by most B-cell lymphomas and B-cell leukemias. These clinical trials have produced the first evidence that genetically-engineered T cells can eliminate CD19-expressing cells in humans.
Light lunch served
Co-sponsored by the David Geffen School of Medicine Initiative in Immunity, Inflammation, Infection, and Transplantation (I3T), the Jonsson Comprehensive Cancer Center, and the Center for AIDS Research